来自官方财务报表的收入、利润与现金流历史。
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
| 利润表 | TTM → 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $1.5B | $606M | $364M | $305M | $245M | $188M | $164M | $136M | $10M | $0M | $0M | $0M | $12M | $12M | $0M | $4M | $7M | $10M | $12M | $8M | $1M |
| 毛利 | $1.3B | $482M | $278M | $240M | $190M | $144M | $125M | $112M | $7M | ($3M) | ($2M) | ($2M) | ($22M) | ($18M) | ($21M) | $4M | $7M | $10M | $12M | $7M | $0M |
| 毛利率% | 84.2% | 79.4% | 76.4% | 78.5% | 77.5% | 76.6% | 75.8% | 82.3% | 75.4% | — | — | — | -191.6% | -157.8% | — | 100.0% | 100.0% | 100.0% | 100.0% | 92.3% | -50.3% |
| 营业利润（EBIT） | — | ($1.2B) | ($878M) | ($710M) | ($457M) | ($375M) | ($265M) | ($235M) | ($307M) | ($189M) | ($173M) | ($117M) | ($87M) | ($55M) | ($42M) | ($62M) | ($8M) | ($9M) | ($14M) | ($20M) | ($54M) |
| 营业利润率% | — | -194.0% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% | -3124.9% | — | — | — | -759.7% | -478.4% | — | -1397.3% | -116.9% | -83.6% | -123.2% | -271.5% | -5486.7% |
| 净利 | ($605M) | ($1.3B) | ($914M) | ($750M) | ($482M) | ($435M) | ($294M) | ($254M) | ($324M) | ($193M) | ($176M) | ($118M) | ($79M) | ($56M) | ($41M) | ($60M) | ($6M) | $118M | ($16M) | ($20M) | ($56M) |
| 净利润率 % | -39.8% | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3297.2% | — | — | — | -688.3% | -487.6% | — | -1350.8% | -93.0% | 1140.9% | -133.9% | -265.1% | -5664.9% |
| EBITDA | — | ($1.2B) | ($819M) | ($660M) | ($447M) | ($384M) | ($250M) | ($217M) | ($295M) | ($184M) | ($170M) | ($115M) | ($86M) | ($54M) | ($40M) | ($59M) | ($6M) | $120M | ($13M) | ($20M) | ($51M) |
| 每股收益（EPS） | $-2.82 | $-5.98 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 | $-2.85 | $-2.02 | $-1.84 | $-1.60 | $-1.56 | $-2.56 | $-0.49 | $9.30 | $-1.28 | $-1.74 | $-5.89 |
| 已发行股数 (M) | — | 214M | 164M | 140M | 123M | 112M | 98M | 85M | 77M | 67M | 62M | 59M | 43M | 35M | 27M | 23M | 13M | 13M | 12M | 11M | 10M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 INSM 交互式查看器。 /companies/us/INSM
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms